/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Gastroesophageal Cancers | Kohei Shitara, MD
Gastroesophageal Cancers | Kohei Shitara, MD

Gastroesophageal Cancers | Kohei Shitara, MD

Research To Practice | Oncology Videos · Aug 19, 2026

New targeted therapies like zanidatamab (HER2+), zolbetuximab (Claudin 18.2+), and bispecific ADCs are transforming GI cancer treatment.

HER2 Loss in Gastric Cancer After First-Line Therapy Mandates Re-Testing for Second-Line Treatment

Nearly half of HER2-positive gastric cancer patients lose HER2 expression after initial chemotherapy and trastuzumab. This dynamic biomarker status requires re-testing at progression to confirm eligibility for subsequent HER2-targeted therapies like trastuzumab deruxtecan, ensuring the right patients receive the treatment.

Gastroesophageal Cancers | Kohei Shitara, MD thumbnail

Gastroesophageal Cancers | Kohei Shitara, MD

Research To Practice | Oncology Videos·3 months ago

Proactive Management of On-Target GI Toxicity Is Essential for Zolbituximab's Clinical Viability

Zolbituximab causes significant nausea and vomiting as a direct result of binding its Claudin 18.2 target in the stomach. Its clinical success depends on aggressively managing this on-target effect with prophylactic multi-drug antiemetics and adjusted infusion rates, particularly during the initial treatment cycle.

Gastroesophageal Cancers | Kohei Shitara, MD thumbnail

Gastroesophageal Cancers | Kohei Shitara, MD

Research To Practice | Oncology Videos·3 months ago

Rapid Innovation in Oncology Can Outpace Long-Term Clinical Trial Designs, Complicating Results

The Horizon GA-01 trial's control arm became outdated mid-study when a superior standard of care (Keynote 811) was approved. This highlights a critical challenge in drug development: long trial timelines can conflict with rapid progress, making it difficult to compare new agents against the true contemporary standard.

Gastroesophageal Cancers | Kohei Shitara, MD thumbnail

Gastroesophageal Cancers | Kohei Shitara, MD

Research To Practice | Oncology Videos·3 months ago

Next-Gen ADCs Expand Claudin 18.2 Targeting to Low-Expressing Gastric Cancer Patients

While the monoclonal antibody zolbituximab requires high Claudin 18.2 expression (>=75%), newer antibody-drug conjugates (ADCs) like AZD-091 are effective in patients with much lower expression (>=25%). This evolution in drug modality significantly broadens the eligible patient population for a given therapeutic target.

Gastroesophageal Cancers | Kohei Shitara, MD thumbnail

Gastroesophageal Cancers | Kohei Shitara, MD

Research To Practice | Oncology Videos·3 months ago